Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Total Current Liabilities of $305.5 million for Q1 2026, up 0.99% year-over-year from $302.5 million in Q1 2025, and up 10.25% quarter-over-quarter from $277.1 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $305.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 0.99% year-over-year to $305.5 million; the TTM figure through Mar 2026 stood at $305.5 million (up 0.99% YoY), while the FY2025 annual figure was $277.1 million, down 29.82% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $305.5 million, up from $277.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $394.9 million in Q4 2024, with the low at $116.6 million in Q3 2022.
- The 5-year median for Total Current Liabilities is $277.1 million (2025), against an average of $255.0 million.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 102.38% in 2023, then dropped 29.82% in 2025.
- Acadia Pharmaceuticals' Total Current Liabilities stood at $125.6 million in 2022, then surged by 102.38% to $254.3 million in 2023, then jumped by 55.31% to $394.9 million in 2024, then decreased by 29.82% to $277.1 million in 2025, then rose by 10.25% to $305.5 million in 2026.
- Business Quant data shows ACAD's Total Current Liabilities at $305.5 million in Q1 2026, $277.1 million in Q4 2025, and $356.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 361.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 361.44 Mn |
| Mar 31, 2026 | 305.52 Mn |
| Dec 31, 2025 | 277.11 Mn |
| Sep 30, 2025 | 356.58 Mn |
| Jun 30, 2025 | 330.02 Mn |
| Mar 31, 2025 | 302.53 Mn |
| Dec 31, 2024 | 394.87 Mn |
| Sep 30, 2024 | 343.95 Mn |
| Jun 30, 2024 | 337.85 Mn |
| Mar 31, 2024 | 330.60 Mn |
| Dec 31, 2023 | 254.25 Mn |
| Sep 30, 2023 | 209.60 Mn |
| Jun 30, 2023 | 187.94 Mn |
| Mar 31, 2023 | 224.30 Mn |
| Dec 31, 2022 | 125.63 Mn |
| Sep 30, 2022 | 116.57 Mn |
| Jun 30, 2022 | 117.68 Mn |
| Mar 31, 2022 | 119.60 Mn |
| Dec 31, 2021 | 96.07 Mn |
| Sep 30, 2021 | 88.22 Mn |